Compounds > mifepristone
Page last updated: 2024-08-23

mifepristone and Embryopathies

mifepristone has been researched along with Embryopathies in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's5 (62.50)29.6817
2010's1 (12.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Barker, E; Latta, K; Laursen, L; Testani, E; York, SL1
Abreu, P; Alfirevic, Z; Navaratnam, K; Sharp, A1
Ford, SM; Lim, K; Scherf, C; Willmott, FJ1
Creemers, JW; Ebbers, S; Lotgering, FK1
Liggitt, D; Nelson, AM; Ware, CB1
Bruinse, HW; Christiaens, GC; De Heus, R; Graziosi, GC; Mol, BW1
Heydanus, R; Papatsonis, DN; Verhulsdonk, MT1
Fletcher, JC1

Reviews

1 review(s) available for mifepristone and Embryopathies

ArticleYear
Rupture of uterus in the first trimester during medical termination of pregnancy for exomphalos using mifepristone/misoprostol.
    BJOG : an international journal of obstetrics and gynaecology, 2008, Volume: 115, Issue:12

    Topics: Abdominal Pain; Abortifacient Agents, Nonsteroidal; Abortion, Therapeutic; Administration, Intravaginal; Administration, Oral; Adult; Drug Therapy, Combination; Female; Fetal Diseases; Hernia, Umbilical; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Ultrasonography; Uterine Rupture

2008

Other Studies

7 other study(ies) available for mifepristone and Embryopathies

ArticleYear
Complications of second-trimester medical termination of pregnancy for fetal anomalies compared with intrauterine fetal demise.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023, Volume: 160, Issue:1

    Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Stillbirth

2023
Short versus Standard Mifepristone and Misoprostol Regimen for Second- and Third-Trimester Termination of Pregnancy for Fetal Anomaly.
    Fetal diagnosis and therapy, 2016, Volume: 39, Issue:2

    Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies

2016
[Termination of pregnancy in the 2nd trimester: mifepriston/misoprostol preferable to sulprostone].
    Nederlands tijdschrift voor geneeskunde, 2009, Volume: 153

    Topics: Abortifacient Agents; Abortion, Induced; Adult; Cohort Studies; Dinoprostone; Female; Fetal Diseases; Humans; Middle Aged; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Young Adult

2009
Late gestation modulation of fetal glucocorticoid effects requires the receptor for leukemia inhibitory factor: an observational study.
    Reproductive biology and endocrinology : RB&E, 2003, May-16, Volume: 1

    Topics: Abnormalities, Multiple; Adrenalectomy; Adrenocorticotropic Hormone; Animals; Bone Diseases, Metabolic; Corticosterone; Female; Fetal Diseases; Fetus; Genes, Lethal; Gestational Age; Homeostasis; Hormone Antagonists; Hypothalamo-Hypophyseal System; Interleukin-6; Leukemia Inhibitory Factor; Leukemia Inhibitory Factor Receptor alpha Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mifepristone; Muscle, Skeletal; Neuroglia; Neuroimmunomodulation; Pituitary-Adrenal System; Pregnancy; Proteins; Receptors, Cytokine; Receptors, Glucocorticoid; Receptors, OSM-LIF; Specific Pathogen-Free Organisms; Spinal Cord

2003
Medical management for termination of second and third trimester pregnancies: a comparison of strategies.
    European journal of obstetrics, gynecology, and reproductive biology, 2004, Sep-10, Volume: 116, Issue:1

    Topics: Abortifacient Agents; Abortion, Induced; Dinoprostone; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies; Treatment Outcome

2004
[Results of pregnancy termination for foetal congenital or chromosomal disorders or intrauterine foetal death by oral mifepristone and/or intravaginal misoprostol; results of a retrospective study].
    Nederlands tijdschrift voor geneeskunde, 2007, Apr-07, Volume: 151, Issue:14

    Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome

2007
Abortion politics, science, and research ethics: take down the wall of separation.
    The Journal of contemporary health law and policy, 1992,Spring, Volume: 8

    Topics: Aborted Fetus; Abortion, Induced; Advisory Committees; Altruism; Beneficence; Biomedical Research; Complicity; Embryo, Mammalian; Ethics; Federal Government; Fertilization in Vitro; Fetal Diseases; Fetal Research; Fetal Tissue Transplantation; Fetus; Financial Support; Genetic Therapy; Government; Government Regulation; Guidelines as Topic; Humans; Mifepristone; Morals; Motivation; National Institutes of Health (U.S.); Pharmaceutical Preparations; Policy Making; Pregnancy; Pregnant Women; Public Policy; Research; Risk; Risk Assessment; Social Control, Formal; Social Justice; Stress, Psychological; United States; United States Dept. of Health and Human Services

1992